Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
Go back to Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy| Gilead Sciences (NASDAQ: GILD) | Delayed: 124.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.87 | 52 Week High | $108.63 | |||
| Open | $124.87 | 52 Week Low | $71.39 | |||
| Day High | $124.87 | P/E | 68.99 | |||
| Day Low | $124.87 | EPS | $1.81 | |||
| Volume | 7,370 | |||||
